Curis Inc (CRIS) stock
CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/3092% below fair value
$0.61+0.07 (+13.38%)
Close on Nov 18, 2026Market cap $1.28MP/E –Yield –
Curis net income
Net income is the profit left for shareholders after every expense, interest and tax.
Curis's net income for the twelve months ending Jun 30, 2026 was -$21.15M. For fiscal 2025 it was -$7.58M. The highest annual figure on record is -$4.44M in fiscal 2010.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.58M | – |
| FY2024 | Dec 31, 2024 | -$43.39M | – |
| FY2023 | Dec 31, 2023 | -$47.41M | – |
| FY2022 | Dec 31, 2022 | -$56.67M | – |
| FY2021 | Dec 31, 2021 | -$45.44M | – |
| FY2020 | Dec 31, 2020 | -$29.91M | – |
| FY2019 | Dec 31, 2019 | -$32.14M | – |
| FY2018 | Dec 31, 2018 | -$32.58M | – |
| FY2017 | Dec 31, 2017 | -$53.32M | – |
| FY2016 | Dec 31, 2016 | -$60.41M | – |
| FY2015 | Dec 31, 2015 | -$58.98M | – |
| FY2014 | Dec 31, 2014 | -$18.73M | – |
| FY2013 | Dec 31, 2013 | -$12.32M | – |
| FY2012 | Dec 31, 2012 | -$16.42M | – |
| FY2011 | Dec 31, 2011 | -$9.86M | – |
| FY2010 | Dec 31, 2010 | -$4.44M | – |
| FY2009 | Dec 31, 2009 | -$9.82M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.58M | – |
| Q1 FY2026 | Mar 31, 2026 | -$24.20M | – |
| Q4 FY2025 | Dec 31, 2025 | $19.36M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.73M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.59M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.62M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.62M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.09M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.80M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.88M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.71M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.18M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.96M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.56M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.33M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.29M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.94M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.11M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.62M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.05M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.84M | – |
| Q1 FY2021 | Mar 31, 2021 | -$9.93M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.52M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.97M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.71M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.71M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.61M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.44M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.21M | – |
| Q1 FY2019 | Mar 31, 2019 | -$9.88M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.94M | – |
| Q3 FY2018 | Sep 30, 2018 | -$7.22M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.66M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.75M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.03M | – |
| Q3 FY2017 | Sep 30, 2017 | -$15.46M | – |
| Q2 FY2017 | Jun 30, 2017 | -$14.09M | – |
| Q1 FY2017 | Mar 31, 2017 | -$15.74M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.34M | – |
| Q3 FY2016 | Sep 30, 2016 | -$28.35M | – |
See a number that looks wrong?